Cidara Therapeutics, Inc. (NASDAQ:CDTX) has been assigned an average rating of “Buy” from the twelve research firms that are currently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, eight have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $14.28.

Several brokerages have issued reports on CDTX. WBB Securities raised Cidara Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. Cantor Fitzgerald reissued an “overweight” rating on shares of Cidara Therapeutics in a research note on Friday, August 11th. ValuEngine raised Cidara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, July 14th. Zacks Investment Research lowered Cidara Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Finally, Wedbush reissued an “outperform” rating and issued a $13.00 price target on shares of Cidara Therapeutics in a research note on Tuesday, May 16th.

ILLEGAL ACTIVITY WARNING: “Cidara Therapeutics, Inc. (CDTX) Receives Consensus Recommendation of “Buy” from Analysts” was first published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The original version of this piece can be viewed at https://www.watchlistnews.com/cidara-therapeutics-inc-cdtx-receives-consensus-recommendation-of-buy-from-analysts/1518771.html.

Cidara Therapeutics (CDTX) remained flat at $6.75 on Wednesday. The company had a trading volume of 143,055 shares. The company has a 50-day moving average price of $7.08 and a 200 day moving average price of $7.32. The firm’s market cap is $113.83 million. Cidara Therapeutics has a 12 month low of $5.60 and a 12 month high of $12.95.

Cidara Therapeutics (NASDAQ:CDTX) last announced its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.99) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.91) by $0.08. Equities analysts expect that Cidara Therapeutics will post ($3.62) EPS for the current fiscal year.

In other news, insider Taylor Sandison bought 20,000 shares of the stock in a transaction dated Wednesday, June 7th. The shares were bought at an average cost of $5.90 per share, with a total value of $118,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jeffrey Stein bought 15,000 shares of the stock in a transaction dated Monday, June 5th. The shares were purchased at an average cost of $5.95 per share, for a total transaction of $89,250.00. The disclosure for this purchase can be found here. 18.90% of the stock is owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in CDTX. Trexquant Investment LP bought a new stake in Cidara Therapeutics during the second quarter worth approximately $110,000. Citadel Advisors LLC bought a new stake in Cidara Therapeutics during the second quarter worth approximately $129,000. Raymond James Financial Services Advisors Inc. bought a new stake in Cidara Therapeutics during the second quarter worth approximately $131,000. Teachers Advisors LLC raised its stake in Cidara Therapeutics by 17.5% in the fourth quarter. Teachers Advisors LLC now owns 16,524 shares of the biotechnology company’s stock worth $172,000 after buying an additional 2,458 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its stake in Cidara Therapeutics by 455.6% in the first quarter. JPMorgan Chase & Co. now owns 25,639 shares of the biotechnology company’s stock worth $200,000 after buying an additional 21,024 shares during the last quarter. 68.22% of the stock is owned by institutional investors and hedge funds.

About Cidara Therapeutics

Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.

Analyst Recommendations for Cidara Therapeutics (NASDAQ:CDTX)

Receive News & Ratings for Cidara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.